Member Info for alfista

Fully respect your decision to sell. Each to their own.

Nobody is forced to buy, hold, or sell are they. Why does someone spend eight and a half years, under several aliases, lecturing readers about their own personal interpretation and subsequent decisions regarding this, or any, share? This question is entirely rhetorical, the answer being so obvious.

The Company expects that these strongly positive announcements and initiatives will have a beneficial effect on the current and future commercial prospects for Fruitflow. The Company is well placed to maximise the commercial opportunities arising from these developments for Fruitflow and the Provexis business, and remains positive about the outlook for the business for the second half of the year and beyond.'

The Company expects that these strongly positive announcements and initiatives will have a beneficial effect on the current and future commercial prospects for Fruitflow. The Company is well placed to maximise the commercial opportunities arising from these developments for Fruitflow and the Provexis business, and remains positive about the outlook for the business for the second half of the year and beyond.'

He'll say what he's paid to say IMO

And you know this. How?

The number of Fruitflow launches from German companies? Would they be launching of blind fait, or do they have feedback that established products are seeing good uptake? Some posters have written that they don't see any growth in European sales, and the bald figures support that view, However, I don't believe there would be so many "me too" launches unless DSM were able to convince brands of the viability. Just saying

http://www.agilpharma.de/index.afp?&CMD=KAT_GEISTIGEL&PROD=1001017092#page=page-1

Thanks gixer, should've read it more thoroughly. So actual sales revenues are about a third up.

Correct me if I'm wrong, but didn't last year's inters include the marketing contribution from DSM in revenues? If so, the real revenue growth was greater than it appears. Agree with you Kievsky, there can also be distortion due to timing of re=orders.

See what you're saying, but I do think it's a very complex calc. If Fruitflow + Omega3 is a model of how a product is launched, then there is a contribution to start up costs coming in from DSM. How they treat such promo sums is open to debate, they make sure we'll never know for certain, but it could be that they amortise it against a projected lifespan, rather than write it all off in the year it was incurred. Just a hypothesis, terms of the AA will remain forever secret. As you say, the pipeline may continue to be longer, but what comes out of it does matter.

Curate's egg. Provexis retail rev's beginning to establish, still at base camp IMO. Additional sales channels including listings with major retailer should produce growth. USA market entry has much more potential, but there will be associated costs to establish and promote. AA rev's from DSM a dampener, gets me wondering if there is some kind of smoothing of flows, otherwise the comment about revenues being at new, all time, highs wouldn't figure. China is, of course, the biggie on the near horizon. Extra costs of establishing new patents is a valuable investment, as is continuing research in the BP reduction. More exposure to medical professionals is vital. Cash constraints, not easy to achieve growth whilst being so prudent. Are they going to try to break out of that cycle using the raised funds? I believe that the backers of the last two fundings will have some influence. As ever with financials, they are seen long after the period, and so we move on. A Happy, healthy, an prosperous New Year to all.

A topic on Radio 5 this morning was whether the NHS should fund lifestyle changes as an alternative to drugs. The doctor interviewed was in favour of trying to wean patients off drugs where possible, as the side effects often created more health issues. Exercise and diet changes are proven to improve lives, but the fight is against sedentary habits and junk food, both of which are heavily promoted. Fruitflow on the NHS may be cost effective overall due to the absence of side effects, but still I'd be surprised to see it.

Merry Christmas all. Have a really nice one.

There there, feel better now?

History has no bearing on shares. Wrong on the headcount. Fruitflow isn't produced by Provexis, is only recently sold by Provexis as a retail product, no headcount involved in that. Marketing to all other Fruitflow brands is by DSM, which has many thousands of heads. If you short term trade things, fine, but I'd have thought it would require more focus. Not emotional at all, just have a very different way of looking at companies. Not defensive except when I read distortions, shares is about facts. So, you looked in and thought you'd post a bit of nonsense, eight years out of date. Takes all sort I guess.

The difference is:- You refer to the past, which has gone and nobody can do a thing about it. I refer to the present and the future, which is all real and valid. You can't be bothered to study that, fine, your choice. Just can't figure out what you have to gain by talking vague, half invented history.

Yes, syrup form was all there was in that period, and it wasn't the format for the nutraceutical future of Fruitflow. So, DSM and Provexis developed Fruitflow powder, enabling the launch of a large variety of brands to enter the market with tablet/capsule solutions. That caused delays, but it is what the market demands. As for 22p, that is a myth, regurgitated by those who weren't watching at the time,to suit their agenda. Vastly more research, more patents, more consumer products across the globe, new joint venture with China mega retailer By Health, additional health claims, particularly sports recovery, blood pressure reduction, and fighting the effects of urban pollution, added along the way. Please don't buy in on the strength of all that practical progress though.

Glad to learn that. Have you followed what has happened since 09? It was only a lab test product back then. It isn't now.

Not circulating that old garbage are you? Did Provexis get ramped and spiked, yes. Has the business moved in the intervening time, from a lab project with a single guinea pig product, to a growing list of brands across the world, including some sizeable companies, yes. Not in the slightest grumpy, just don't accept that recycling trashy eight year old jokes is valid.